Published in Cochrane Database Syst Rev on April 15, 2009
Management of trypanosomiasis and leishmaniasis. Br Med Bull (2012) 1.78
Leishmaniasis: clinical syndromes and treatment. QJM (2013) 1.27
Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am J Trop Med Hyg (2013) 1.07
Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg (2010) 1.04
Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis (2013) 1.03
Antiparasitic therapy. Mayo Clin Proc (2011) 0.98
Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update. PLoS One (2013) 0.95
Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg (2012) 0.94
Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol (2015) 0.93
Importance of nonenteric protozoan infections in immunocompromised people. Clin Microbiol Rev (2010) 0.92
Manifestations of paediatric Leishmania infantum infections in Malta. Travel Med Infect Dis (2011) 0.90
Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide. PLoS Negl Trop Dis (2014) 0.88
Drug resistance analysis by next generation sequencing in Leishmania. Int J Parasitol Drugs Drug Resist (2014) 0.87
Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials (2012) 0.87
Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1. PLoS Negl Trop Dis (2015) 0.86
Drug Strategies Targeting CYP51 in Neglected Tropical Diseases. Chem Rev (2014) 0.86
Vector and reservoir control for preventing leishmaniasis. Cochrane Database Syst Rev (2015) 0.85
Systemic therapy of New World cutaneous leishmaniasis: A case report and review article. Can J Infect Dis Med Microbiol (2010) 0.85
In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites. PLoS Negl Trop Dis (2012) 0.85
The Cure Rate after Placebo or No Therapy in American Cutaneous Leishmaniasis: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.85
The effect of (-)-epigallocatechin 3-O--gallate in vitro and in vivo in Leishmania braziliensis: involvement of reactive oxygen species as a mechanism of action. PLoS Negl Trop Dis (2014) 0.81
Clinical and epidemiologic profile of cutaneous leishmaniasis in Colombian children: considerations for local treatment. Am J Trop Med Hyg (2013) 0.79
Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials. PLoS One (2015) 0.78
Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic Review. PLoS Negl Trop Dis (2016) 0.77
A Multiplatform Metabolomic Approach to the Basis of Antimonial Action and Resistance in Leishmania infantum. PLoS One (2015) 0.76
Specific and nonhomologous isofunctional enzymes of the genetic information processing pathways as potential therapeutical targets for tritryps. Enzyme Res (2011) 0.76
Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. Antimicrob Agents Chemother (2014) 0.75
Recurrent cutaneous leishmaniasis. An Bras Dermatol (2013) 0.75
Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre. Mem Inst Oswaldo Cruz (2016) 0.75
The Cochrane Skin Group: a vanguard for developing and promoting evidence-based dermatology. J Evid Based Med (2013) 0.75
Nutritional status in patients with cutaneous leishmaniasis and a study of the effects of zinc supplementation together with antimony treatment. Food Nutr Res (2014) 0.75
The impact of human immunodeficiency virus (HIV) co-infection on the economic burden of cutaneous leishmaniasis (CL) in Brazil and potential value of new CL drug treatments. Am J Trop Med Hyg (2014) 0.75
Calmodulin Polymerase Chain Reaction-Restriction Fragment Length Polymorphism for Leishmania Identification and Typing. Am J Trop Med Hyg (2016) 0.75
Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis. PLoS Negl Trop Dis (2017) 0.75
Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil. PLoS One (2017) 0.75
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 7.36
Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis (2008) 3.27
Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis (2011) 2.19
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17
Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol (2002) 2.07
Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 2.02
Combination therapy for visceral leishmaniasis. Lancet Infect Dis (2010) 1.96
Of cattle, sand flies and men: a systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination. PLoS Negl Trop Dis (2010) 1.90
Leishmania/HIV co-infections in the second decade. Indian J Med Res (2006) 1.73
Reporting of methodologic information on trial registries for quality assessment: a study of trial records retrieved from the WHO search portal. PLoS One (2010) 1.66
Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased? Chest (2006) 1.58
Interventions for vitiligo. Cochrane Database Syst Rev (2015) 1.57
Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev (2008) 1.35
Interventions for vitiligo. Cochrane Database Syst Rev (2010) 1.35
Natural history of a visceral leishmaniasis outbreak in highland Ethiopia. Am J Trop Med Hyg (2009) 1.29
Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol (2006) 1.26
Risk factors for visceral leishmaniasis in a new epidemic site in Amhara Region, Ethiopia. Am J Trop Med Hyg (2009) 1.25
Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs (2009) 1.23
Population movement: a key factor in the epidemiology of neglected tropical diseases. Trop Med Int Health (2010) 1.16
Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother (2003) 1.15
Risk factors for visceral Leishmaniasis among residents and migrants in Kafta-Humera, Ethiopia. PLoS Negl Trop Dis (2013) 1.07
Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother (2004) 1.06
A model of chronic inflammation and pulmonary emphysema after multiple ozone exposures in mice. Am J Physiol Lung Cell Mol Physiol (2011) 1.06
Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev (2010) 1.05
Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis (2013) 1.03
Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis (2010) 1.02
Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1. J Infect Dis (2002) 1.01
Evaluation of two rK39 dipstick tests, direct agglutination test, and indirect fluorescent antibody test for diagnosis of visceral leishmaniasis in a new epidemic site in highland Ethiopia. Am J Trop Med Hyg (2011) 1.00
Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: a Mechanisms of the Development of Allergy (MeDALL) seminar. J Allergy Clin Immunol (2012) 0.93
Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet Immunol Immunopathol (2005) 0.92
Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine (2008) 0.89
Guidelines for designing and reporting clinical trials in vitiligo. Arch Dermatol (2011) 0.89
Endemic transmission of visceral leishmaniasis in Bhutan. Am J Trop Med Hyg (2012) 0.88
Virulence and disease in leishmaniasis: what is relevant for the patient? Trends Parasitol (2004) 0.86
Evidence for a wide occurrence of proton-translocating pyrophosphatase genes in parasitic and free-living protozoa. Biochem Biophys Res Commun (2002) 0.86
Epidemiology of leishmaniasis in Spain based on hospitalization records (1997-2008). Am J Trop Med Hyg (2011) 0.86
Multilocus microsatellite typing revealed high genetic variability of Leishmania donovani strains isolated during and after a Kala-azar epidemic in Libo Kemkem district, northwest Ethiopia. Microbes Infect (2011) 0.85
Vector and reservoir control for preventing leishmaniasis. Cochrane Database Syst Rev (2015) 0.85
Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp. Exp Parasitol (2010) 0.83
[Antiparasite therapy]. Enferm Infecc Microbiol Clin (2003) 0.82
Different strains of mice present distinct lung tissue mechanics and extracellular matrix composition in a model of chronic allergic asthma. Respir Physiol Neurobiol (2008) 0.81
The leishmaniasis e-compendium: a geo-referenced bibliographic tool. Trends Parasitol (2010) 0.81
Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health Organization. PLoS Med (2006) 0.81
The development of the MeDALL Core Questionnaires for a harmonized follow-up assessment of eleven European birth cohorts on asthma and allergies. Int Arch Allergy Immunol (2014) 0.79
Integrated Allergy and Asthma Prevention and Care: Report of the MeDALL/AIRWAYS ICPs Meeting at the Ministry of Health and Care Services, Oslo, Norway. Int Arch Allergy Immunol (2015) 0.78
Isolation and characterization of Leishmania infantum cDNA encoding a protein homologous to eukaryotic elongation factor 1 gamma. Trans R Soc Trop Med Hyg (2002) 0.76
Comment on: Vitiligo Treatment in Childhood: a State of the Art Review. By Tamesis MEB, Morelli JG: Pediatric Dermatology 2010;27(5):437-455. Pediatr Dermatol (2011) 0.75
Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev (2017) 0.75
Correction: Risk of bias and confounding of observational studies of Zika virus infection: A scoping review of research protocols. PLoS One (2017) 0.75
Environmental Factors as Key Determinants for Visceral Leishmaniasis in Solid Organ Transplant Recipients, Madrid, Spain. Emerg Infect Dis (2017) 0.75